User login
Dr Anne Peters, of the Keck School of Medicine of the University of Southern California, reports on the latest research on insulin therapy in adults with type 2 diabetes, presented at the European Association for the Study of Diabetes (EASD).
Dr Peters highlights a clinical study evaluating whether bedtime is optimal for the administration of neutral protamine Hagedorn (NPH) insulin, also known as isophane insulin. The results indicate that titration of NPH plays an important role in avoiding nocturnal hypoglycemia.
Next, Dr Peters discusses the ONWARDS 2 study, a phase 3a trial looking at once-weekly insulin icodec vs once-daily insulin degludec in basal insulin–treated type 2 diabetes. The trial found insulin icodec to be superior to insulin degludec in reducing A1c.
Dr Peters also examines the SoliMix trial, which compared iGlarLixi once daily to twice-daily premix BIAsp 30 in suboptimally controlled type 2 diabetes. The trial evaluated whether patients currently on a basal-bolus regimen would have an equal or more effective response to once-a-day combination therapy. Results showed that iGlarLixi provided better glycemic control and weight benefit than the twice-daily BlAsp 30.
Finally, Dr Peters evaluates a study that looked at switching from a basal-bolus insulin treatment to insulin degludec + liraglutide combination. The combination proved at least as effective as the basal-bolus approach.
--
Anne L. Peters, MD, Professor, Department of Clinical Medicine, Clinical Scholar, Keck School of Medicine of the University of Southern California; Director, USC Clinical Diabetes Programs, University of Southern California Westside Center for Diabetes, Los Angeles, California
Anne L. Peters, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or a trustee for: AstraZeneca; Lilly; NovoNordisk; Abbott; Vertex; Zealand; ShouTi
Received research grant from: Insulet; Dexcom; Abbott
Received income in an amount equal to or greater than $250 from: AstraZeneca; Lilly; NovoNordisk; Abbott; Vertex; Zealand; ShouTi; Insulet; Dexcom
Stock options from: Teladoc; Omada Health (not even close to 5% equity)
Dr Anne Peters, of the Keck School of Medicine of the University of Southern California, reports on the latest research on insulin therapy in adults with type 2 diabetes, presented at the European Association for the Study of Diabetes (EASD).
Dr Peters highlights a clinical study evaluating whether bedtime is optimal for the administration of neutral protamine Hagedorn (NPH) insulin, also known as isophane insulin. The results indicate that titration of NPH plays an important role in avoiding nocturnal hypoglycemia.
Next, Dr Peters discusses the ONWARDS 2 study, a phase 3a trial looking at once-weekly insulin icodec vs once-daily insulin degludec in basal insulin–treated type 2 diabetes. The trial found insulin icodec to be superior to insulin degludec in reducing A1c.
Dr Peters also examines the SoliMix trial, which compared iGlarLixi once daily to twice-daily premix BIAsp 30 in suboptimally controlled type 2 diabetes. The trial evaluated whether patients currently on a basal-bolus regimen would have an equal or more effective response to once-a-day combination therapy. Results showed that iGlarLixi provided better glycemic control and weight benefit than the twice-daily BlAsp 30.
Finally, Dr Peters evaluates a study that looked at switching from a basal-bolus insulin treatment to insulin degludec + liraglutide combination. The combination proved at least as effective as the basal-bolus approach.
--
Anne L. Peters, MD, Professor, Department of Clinical Medicine, Clinical Scholar, Keck School of Medicine of the University of Southern California; Director, USC Clinical Diabetes Programs, University of Southern California Westside Center for Diabetes, Los Angeles, California
Anne L. Peters, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or a trustee for: AstraZeneca; Lilly; NovoNordisk; Abbott; Vertex; Zealand; ShouTi
Received research grant from: Insulet; Dexcom; Abbott
Received income in an amount equal to or greater than $250 from: AstraZeneca; Lilly; NovoNordisk; Abbott; Vertex; Zealand; ShouTi; Insulet; Dexcom
Stock options from: Teladoc; Omada Health (not even close to 5% equity)
Dr Anne Peters, of the Keck School of Medicine of the University of Southern California, reports on the latest research on insulin therapy in adults with type 2 diabetes, presented at the European Association for the Study of Diabetes (EASD).
Dr Peters highlights a clinical study evaluating whether bedtime is optimal for the administration of neutral protamine Hagedorn (NPH) insulin, also known as isophane insulin. The results indicate that titration of NPH plays an important role in avoiding nocturnal hypoglycemia.
Next, Dr Peters discusses the ONWARDS 2 study, a phase 3a trial looking at once-weekly insulin icodec vs once-daily insulin degludec in basal insulin–treated type 2 diabetes. The trial found insulin icodec to be superior to insulin degludec in reducing A1c.
Dr Peters also examines the SoliMix trial, which compared iGlarLixi once daily to twice-daily premix BIAsp 30 in suboptimally controlled type 2 diabetes. The trial evaluated whether patients currently on a basal-bolus regimen would have an equal or more effective response to once-a-day combination therapy. Results showed that iGlarLixi provided better glycemic control and weight benefit than the twice-daily BlAsp 30.
Finally, Dr Peters evaluates a study that looked at switching from a basal-bolus insulin treatment to insulin degludec + liraglutide combination. The combination proved at least as effective as the basal-bolus approach.
--
Anne L. Peters, MD, Professor, Department of Clinical Medicine, Clinical Scholar, Keck School of Medicine of the University of Southern California; Director, USC Clinical Diabetes Programs, University of Southern California Westside Center for Diabetes, Los Angeles, California
Anne L. Peters, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or a trustee for: AstraZeneca; Lilly; NovoNordisk; Abbott; Vertex; Zealand; ShouTi
Received research grant from: Insulet; Dexcom; Abbott
Received income in an amount equal to or greater than $250 from: AstraZeneca; Lilly; NovoNordisk; Abbott; Vertex; Zealand; ShouTi; Insulet; Dexcom
Stock options from: Teladoc; Omada Health (not even close to 5% equity)
